Priya Ranjan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Priya Ranjan has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Amrita Kumar
Virology Group, International Centre for Genetic Engineering & Biotechnology, New Delhi, 110067, India
2 shared publicationsJacqueline M. Katz
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
2 shared publicationsShivaprakash Gangappa
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
2 shared publicationsSuryaprakash Sambhara
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
2 shared publications- Suryaprakash Sambhara
Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
2 shared publications - Takashi Fujita
Division of Integrated Life Science, Graduate School of Biostudies, Kyoto University, Kyoto, Japan
2 shared publications
Latest Publications
- 1 April 2020
- Published by Elsevier in Antiviral Research
- Vol. 176, 104747
Influenza virus NS1-C/EBPβ gene regulatory complex inhibits RIG-I transcription
- 1 April 2020
- Published by Elsevier in Antiviral Research
- Vol. 176, 104747
Influenza virus NS1-C/EBPβ gene regulatory complex inhibits RIG-I transcription
- Open Access
- 18 November 2014
- Published by Wiley in European Journal of Immunology
- Vol. 45 (3) , 758-772
NLRC5 interacts with RIG‐I to induce a robust antiviral response against influenza virus infection
The NLR protein, NLRC5 is an important regulator of MHC class I gene expression, however, the role of NLRC5 in other innate immune responses is less well defined. In the present study, we report that NLRC5 binds RIG‐I and that this interaction is critical for robust antiviral responses against influenza virus. Overexpression of NLRC5 in the human lung epithelial cell line, A549, and normal human bronchial epithelial cells resulted in impaired replication of influenza virus A/Puerto Rico/8/34 virus (PR8) and enhanced IFN‐β expression. Influenza virus leads to induction of IFN‐β that drives RIG‐I and NLRC5 expression in host cells. Our results suggest that NLRC5 extends and stabilizes influenza virus induced RIG‐I expression and delays expression of the viral inhibitor protein NS1. We show that NS1 binds to NLRC5 to suppress its function. Interaction domain mapping revealed that NLRC5 interacts with RIG‐I via its N‐terminal death domain and that NLRC5 enhanced antiviral activity in an leucine‐rich repeat domain independent manner. Taken together, our findings identify a novel role for NLRC5 in RIG‐I‐mediated antiviral host responses against influenza virus infection, distinguished from the role of NLRC5 in MHC class I gene regulation.
- 18 November 2014
- Published by Wiley in European Journal of Immunology
- Vol. 45 (3) , 758-772
Open AccessNLRC5 interacts with RIG‐I to induce a robust antiviral response against influenza virus infection
The NLR protein, NLRC5 is an important regulator of MHC class I gene expression, however, the role of NLRC5 in other innate immune responses is less well defined. In the present study, we report that NLRC5 binds RIG‐I and that this interaction is critical for robust antiviral responses against influenza virus. Overexpression of NLRC5 in the human lung epithelial cell line, A549, and normal human bronchial epithelial cells resulted in impaired replication of influenza virus A/Puerto Rico/8/34 virus (PR8) and enhanced IFN‐β expression. Influenza virus leads to induction of IFN‐β that drives RIG‐I and NLRC5 expression in host cells. Our results suggest that NLRC5 extends and stabilizes influenza virus induced RIG‐I expression and delays expression of the viral inhibitor protein NS1. We show that NS1 binds to NLRC5 to suppress its function. Interaction domain mapping revealed that NLRC5 interacts with RIG‐I via its N‐terminal death domain and that NLRC5 enhanced antiviral activity in an leucine‐rich repeat domain independent manner. Taken together, our findings identify a novel role for NLRC5 in RIG‐I‐mediated antiviral host responses against influenza virus infection, distinguished from the role of NLRC5 in MHC class I gene regulation.
- Open Access
- 21 May 2010
- Published by Springer Nature in Virology Journal
- Vol. 7 (1) , 102
5'PPP-RNA induced RIG-I activation inhibits drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza virus replication
Background: Emergence of drug-resistant strains of influenza viruses, including avian H5N1 with pandemic potential, 1918 and 2009 A/H1N1 pandemic viruses to currently used antiviral agents, neuraminidase inhibitors and M2 Ion channel blockers, underscores the importance of developing novel antiviral strategies. Activation of innate immune pathogen sensor Retinoic Acid Inducible Gene-I (RIG-I) has recently been shown to induce antiviral state. Results: In the present investigation, using real time RT-PCR, immunofluorescence, immunoblot, and plaque assay we show that 5'PPP-containing single stranded RNA (5'PPP-RNA), a ligand for the intracytoplasmic RNA sensor, RIG-I can be used as a prophylactic agent against known drug-resistant avian H5N1 and pandemic influenza viruses. 5'PPP-RNA treatment of human lung epithelial cells inhibited replication of drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza viruses in a RIG-I and type 1 interferon dependant manner. Additionally, 5'PPP-RNA treatment also inhibited 2009 H1N1 viral replication in vivo in mice. Conclusions: Our findings suggest that 5'PPP-RNA mediated activation of RIG-I can suppress replication of influenza viruses irrespective of their genetic make-up, pathogenicity, and drug-sensitivity status.
- 21 May 2010
- Published by Springer Nature in Virology Journal
- Vol. 7 (1) , 102
Open Access5'PPP-RNA induced RIG-I activation inhibits drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza virus replication
Background: Emergence of drug-resistant strains of influenza viruses, including avian H5N1 with pandemic potential, 1918 and 2009 A/H1N1 pandemic viruses to currently used antiviral agents, neuraminidase inhibitors and M2 Ion channel blockers, underscores the importance of developing novel antiviral strategies. Activation of innate immune pathogen sensor Retinoic Acid Inducible Gene-I (RIG-I) has recently been shown to induce antiviral state. Results: In the present investigation, using real time RT-PCR, immunofluorescence, immunoblot, and plaque assay we show that 5'PPP-containing single stranded RNA (5'PPP-RNA), a ligand for the intracytoplasmic RNA sensor, RIG-I can be used as a prophylactic agent against known drug-resistant avian H5N1 and pandemic influenza viruses. 5'PPP-RNA treatment of human lung epithelial cells inhibited replication of drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza viruses in a RIG-I and type 1 interferon dependant manner. Additionally, 5'PPP-RNA treatment also inhibited 2009 H1N1 viral replication in vivo in mice. Conclusions: Our findings suggest that 5'PPP-RNA mediated activation of RIG-I can suppress replication of influenza viruses irrespective of their genetic make-up, pathogenicity, and drug-sensitivity status.
- 28 February 2009
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 20 (1) , 1-5
Antiviral defense: RIG-Ing the immune system to STING
- 28 February 2009
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 20 (1) , 1-5
Antiviral defense: RIG-Ing the immune system to STING